Objective: To evaluate the efficacy and safety of an hydrogen peroxide tooth whitening product (Rembrandt 2-hour White, Den-Mat, Inc.).

Methods: 50 patients were randomly divided into 2 groups. Group 1 subjects were treated with eight 20-minute applications of the peroxide-containing product (Rembrandt 2-Hour White Kit) with a 10-minute break between each application, and the Group 2 subjects were treated the same way with a non-peroxide-containing whitening product. Teeth evaluated were maxillary premolars and anteriors. Subjects were evaluated at baseline, after 4 and 8 applications using spectrophotometer (SpectroShade MHT), shade guide evaluation (Trubyte Bioform, Dentsply), modified gingival index (MGI), plaque index (PI) and patient response questionnaire. Whitening efficacy was determined by evaluating changes from baseline in tooth yellowness (delta b*) and tooth brightness (delta L*). Significance was determined using t-test with a=0.05.

Results: There was a significant initial (0-4 applications) and an overall (0-8 applications) improvement in Group 1 L* values compared to Group 2. Group 1 also showed a significant decrease in yellowness (b* value) compared to Group 2 after the second series of applications. Group 1 showed significant overall decrease in PI values compared to Group 2. MGI values were within the normal range. The Bioform shade of teeth from both groups improved, with the Group 1 teeth exhibiting the change of 2.36 shades and Group 2 of 1.91 shades. The majority of patients felt comfortable during treatment and reported no increase in tooth sensitivity. They felt that the product freshened their breath and whitened their teeth significantly better than Group 2.

Conclusions: The results indicate that the active product significantly improved the teeth's brightness, decreased the yellowness, decreased plaque formation and is safe to use. It is noteworthy that whiteness increased in premolars and anterior teeth as a group. (This research was supported by Den-Mat Inc.)

Back to the Dental Materials: IV - Clinical Trials Program
Back to the IADR/AADR/CADR 82nd General Session (March 10-13, 2004)

Top Level Search